CA
NZ
UK
AU
IND
US
…
Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Caribou Biosciences develops CRISPR-based gene-editing therapies and a platform for engineered cell and in vivo medicines; long-term growth may be driven by progress in clinical-stage programs, platform versatility across modalities, and rising demand for genetic medicines. Investors may find it attractive for its scientific pedigree and a technology base that appears positioned to support collaborations and product development.
Principal risks include clinical and regulatory setbacks, competition from other gene-editing and cell-therapy developers, potential safety and off-target editing issues, and significant financing and execution risk in advancing programs to market.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -148.68M | -149.11M | -101.88M | -99.35M | -66.60M |
| Net income | -148.12M | -149.10M | -102.07M | -99.42M | -66.92M |
| Selling general administrative | 37.91M | 46.46M | 38.46M | 38.02M | 24.32M |
| Selling and marketing expenses | - | - | 3.52M | - | - |
| Gross profit | 7.51M | 6.07M | 30.95M | 13.85M | 9.60M |
| Reconciled depreciation | 3.65M | 3.93M | 3.29M | 1.62M | 0.98M |
| Ebit | -136.19M | -166.62M | -116.06M | -106.40M | -66.98M |
| Ebitda | -132.55M | -162.69M | -112.53M | -106.27M | -68.18M |
| Depreciation and amortization | 3.65M | 3.93M | 3.52M | 0.13M | -1.20M |
| Non operating income net other | - | - | - | 7.05M | 0.25M |
| Operating income | -136.19M | -166.62M | -116.06M | -106.40M | -66.98M |
| Other operating expenses | 147.35M | 176.61M | 150.54M | 120.25M | 76.58M |
| Interest expense | - | - | - | 8.54M | 0.01M |
| Tax provision | -0.55M | -0.01M | 0.19M | 0.07M | 0.32M |
| Interest income | - | - | - | - | 0.15M |
| Net interest income | - | - | - | - | 0.14M |
| Income tax expense | -0.55M | -0.01M | 0.19M | 0.07M | 0.32M |
| Total revenue | 11.16M | 9.99M | 34.48M | 13.85M | 9.60M |
| Total operating expenses | 143.71M | 172.68M | 147.01M | 120.25M | 76.58M |
| Cost of revenue | 3.65M | 3.93M | 3.52M | - | - |
| Total other income expense net | -12.48M | 17.50M | 14.18M | 7.05M | 0.38M |
| Net income from continuing ops | -148.12M | -149.10M | -94.55M | -99.42M | -66.92M |
| Net income applicable to common shares | - | - | - | -99.42M | -66.92M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 175.37M | 313.31M | 440.97M | 373.76M | 442.36M |
| Other current assets | 2.91M | 6.59M | 6.16M | 1.12M | 0.67M |
| Total liab | 53.19M | 60.36M | 72.57M | 72.89M | 54.53M |
| Total stockholder equity | 122.17M | 252.95M | 368.40M | 300.87M | 387.82M |
| Deferred long term liab | - | - | - | - | 24.61M |
| Other current liab | 16.54M | 23.62M | 20.76M | 16.08M | 0.79M |
| Common stock | 0.01M | 0.01M | 0.01M | 0.01M | 0.01M |
| Capital stock | 0.01M | 0.01M | 0.01M | 0.01M | 0.01M |
| Retained earnings | -596.51M | -448.39M | -299.29M | -197.22M | -97.79M |
| Other liab | - | - | - | 17.99M | 28.70M |
| Other assets | - | - | - | 1.54M | 0.97M |
| Cash | 12.36M | 16.29M | 51.16M | 58.34M | 240.42M |
| Total current liabilities | 25.41M | 30.65M | 28.30M | 28.13M | 25.83M |
| Current deferred revenue | 1.90M | 3.13M | 2.85M | 9.94M | 8.70M |
| Net debt | 14.87M | 10.19M | -23.68M | -30.59M | -240.42M |
| Short term debt | 1.20M | 1.43M | 1.58M | 0.97M | 12.35M |
| Short long term debt total | 27.23M | 26.49M | 27.48M | 27.75M | - |
| Other stockholder equity | 718.58M | 701.08M | 667.65M | 499.60M | 43.39M |
| Property plant equipment | - | - | - | 10.68M | 4.89M |
| Total current assets | 145.23M | 219.38M | 338.84M | 260.25M | 391.19M |
| Long term investments | 3.50M | 49.12M | 51.33M | 77.07M | 45.30M |
| Net tangible assets | - | - | - | 300.87M | 387.82M |
| Short term investments | 126.98M | 193.24M | 277.67M | 189.32M | 135.41M |
| Net receivables | 2.98M | 3.25M | 3.86M | 4.66M | 8.12M |
| Inventory | - | - | - | -62.57M | -31.11M |
| Accounts payable | 5.78M | 2.48M | 3.12M | 1.15M | 3.99M |
| Accumulated other comprehensive income | 0.10M | 0.26M | 0.03M | -1.52M | -0.14M |
| Common stock total equity | - | - | - | 0.01M | 0.01M |
| Retained earnings total equity | - | - | - | -197.22M | -97.79M |
| Non currrent assets other | 2.15M | 5.52M | 1.59M | 1.54M | 0.97M |
| Non current assets total | 30.14M | 93.94M | 102.13M | 113.52M | 51.16M |
| Capital lease obligations | 27.23M | 26.49M | 27.11M | 27.75M | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 103.60M | 86.61M | -35.54M | -86.19M | -173.28M |
| Change to liabilities | - | - | - | -0.78M | 34.90M |
| Total cashflows from investing activities | 102.24M | 86.61M | -68.18M | -93.25M | -176.40M |
| Net borrowings | - | - | - | - | 1.03M |
| Total cash from financing activities | 4.82M | 16.72M | 154.30M | 2.13M | 433.43M |
| Change to operating activities | - | - | - | 3.26M | -0.87M |
| Net income | -148.12M | -149.10M | -102.07M | -99.42M | -66.92M |
| Change in cash | -3.93M | -34.87M | -7.18M | -182.08M | 224.51M |
| Begin period cash flow | 16.34M | 51.21M | 58.38M | 240.47M | 15.95M |
| End period cash flow | 12.41M | 16.34M | 51.21M | 58.38M | 240.47M |
| Total cash from operating activities | -110.99M | -138.20M | -93.29M | -90.97M | -32.52M |
| Issuance of capital stock | 4.07M | 15.19M | 152.83M | 0.00M | 429.85M |
| Depreciation | 3.65M | 3.93M | 3.52M | 1.62M | 0.98M |
| Other cashflows from investing activities | 1.14M | -1.61M | - | -0.60M | -1.00M |
| Change to inventory | - | - | - | - | -2.20M |
| Change to account receivables | 0.27M | 0.61M | 0.81M | 0.95M | -1.00M |
| Sale purchase of stock | - | - | - | - | 432.40M |
| Other cashflows from financing activities | - | 1.53M | 1.58M | -93.25M | 112.53M |
| Change to netincome | - | - | - | 11.72M | 1.88M |
| Capital expenditures | 1.36M | 6.50M | 11.61M | 7.05M | 3.12M |
| Change receivables | - | - | - | 4.22M | -2.80M |
| Cash flows other operating | - | - | - | -7.52M | -0.60M |
| Cash and cash equivalents changes | - | - | - | -182.08M | 224.51M |
| Change in working capital | -0.48M | -5.11M | -7.32M | -4.20M | 29.07M |
| Stock based compensation | 12.68M | 16.71M | 13.75M | 11.72M | 3.45M |
| Other non cash items | 21.84M | -4.61M | -1.18M | -0.58M | 2.43M |
| Free cash flow | -112.35M | -144.71M | -104.90M | -98.02M | -35.64M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| CRBU Caribou Biosciences Inc |
-0.03 6.44% |
0.42 | - | - | 13.57 | 1.41 | 5.25 | -36.94 |
| NVO Novo Nordisk A/S |
1.09 2.72% |
41.41 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
3.78 0.69% |
550.87 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
15.61 1.73% |
919.96 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
| Name | Title | Year Born |
|---|---|---|
| Dr. Steven B. Kanner | Chief Scientific Officer | 1959 |
| Dr. Rachel E. Haurwitz Ph.D. | Co-Founder, CEO, Pres & Director | 1986 |
| Mr. Jason V. O'Byrne M.B.A. | Chief Financial Officer | 1969 |
| Ms. Barbara G. McClung Esq., J.D. | Chief Legal Officer & Corp. Sec. | 1955 |
| Mr. Daniel Poon | VP of Operations & Information Technology | NA |
| Dr. Justin Skoble | VP of Technical Operations | NA |
| Ms. Amy Figueroa C.F.A. | VP of Investor Relations & Corp. Communications | NA |
| Ms. Cindy Hayashi | VP of HR | NA |
| Ms. Ruhi A. Khan M.B.A. | Chief Bus. Officer | 1975 |
| Dr. Syed Ali-aamir Rizvi M.D. | Chief Medical Officer | 1967 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+1.88%
Communication Services
+1.14%
Consumer Cyclical
+1.04%
Consumer Defensive
+0.57%
Energy
+0.50%
Financial Services
+0.81%
Financials
+0.24%
Healthcare
+1.35%
Industrials
+1.54%
Real Estate
+0.24%
Technology
+2.32%
Utilities
+0.48%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
-4.40%
Please wait processing your request...